ACTRN12621000981820尚未招募未知
A double-blinded placebo-controlled parallel design trial to determine whether inhibiting intestinal sweet taste sensing improves glycaemic responses in patients with type 2 diabetes
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 79 Years（—）
- 性别
- All
入选标准
- •i) Volunteers with Type 2 Diabetes Mellitus (American Diabetes Association criteria) managed by metformin alone (morning dose of metformin will be withheld until after study day lunch on each visit, to reduce effects on gut hormone responses)
- •ii) HbA1c less than or equal to 8.5%
- •iii) Body mass index (BMI) 25 - 35 kg/m2
- •iv) Haemoglobin above the lower limit of the normal range (i.e. above 135g/L for men and above 115g/L for women), and ferritin above the lower limit of normal (above 20ng/mL for women and above 30ng/mL for men)
- •v) Consumption of more than one low-calorie sweetener (LCS) containing beverage per day, or equivalent
排除标准
- •i) Significant illness, other than type 2 diabetes, including impairment to cardiovascular or respiratory function that limits a participant’s activity and represents a risk to safe placement of a nasoenteral catheter.
- •ii) History of gastrointestinal disease, including significant upper gastrointestinal symptoms (assessed by validated gastrointestinal symptom questionnaire), pancreatitis, or previous gastrointestinal surgery (other than uncomplicated appendectomy or cholecystectomy)
- •iii) Impaired renal or liver function (as assessed by calculated creatinine clearance less than or equal to 90 mL/min or abnormal liver function tests (greater than or equal to 2 times upper limit of normal))
- •iv) Participants medicated with anti-diabetics other than metformin
- •v) Participants unable to self-monitor blood glucose levels
- •vi) Volunteers with body mass index greater than or equal to 20 kg/m2 or less than or equal to 35 kg/m2
- •vii) Donation of blood within the previous 3 months
- •viii) Participation in any other research studies within the previous 3 months
- •ix) Participants medicated with opiates, anticholinergics, levodopa, clonidine, nitrates, phosphodiesterase type 5 inhibitors, sumatriptan, metoclopramide, domperidone, cisapride, prucalopride, or erythromycin
- •x) Evidence of drug abuse, daily consumption of more than 20 g alcohol or 10 cigarettes
- •xi) Female patients not using appropriate contraceptive method (i.e. oral contraceptive pill, diaphragm, DepoProvera hormonal contraceptive injection, intrauterine device, Norplant method)
- •xii) Vegetarian, lactation, or pregnancy
研究者
相似试验
进行中（未招募）
1 期
A double-blind, placebo-controlled, parallel study to evaluate the effects of GW-856553 on endothelial function/ vascular compliance in subjects with dyslipidaemia.GW-856553 is under development as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populationsEUCTR2006-005227-42-GBGlaxoSmithKline Research & Development Ltd
进行中（未招募）
不适用
A study of clinical research intended to estimate the effect of Coruno ® molsidomine, on the dysfunction of the endothelium layer of cells which recover the inside of blood vessels and which plays a role in the dilation and the contraction of vessels as well as in the coagulation of the blood in patients suffering from stable angina pectoris and undergoing a percutaneous coronary intervention.Patients with stable angina undergoing elective PCI, used an add-on treatment on standard care therapy, molsidomine or placebo to improve the endothelial function (12 months treatment)MedDRA version: 14.1Level: LLTClassification code 10011079Term: Coronary artery disease NOSSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-000190-31-BETherabel Pharmaceuticals Ltd
尚未招募
4 期
A randomized, double-blind, placebo parallel controlled clinical trial of Shuanghua Baihe Tablets in the treatment of recurrent aphthous ulcerRecurrent aphthous ulcerITMCTR2000003541Peking University School and Hospital of Stomatology
尚未招募
不适用
A randomized, double-blind, placebo parallel controlled clinical trial of Bushen Huoxue Decoction for treatment of coronary heart disease with kidney deficiency and blood stasis syndromeITMCTR2000003557Guang'anmen Hospital, China Academy of Chinese Medical Sciences
尚未招募
1 期
Study for Screening of Chinese Patent Drugs in the Rehabilitation Treatment of novel coronavirus pneumonia (COVID-19)ovel coronavirus pneumonia (COVID-19)ITMCTR2000003279Hubei Provincial Hospital of TCM